Neverfail

neverfail.com

Neverfail enables IT to meet or exceed service level agreements (SLAs) by providing continuous availability and connectivity to applications, data, and infrastructure. We do this by providing bullet-proof technology, industry-leading experience, and a complete dedication to customer success.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

ATHERSYS AMENDS SECURITIES PURCHASE AGREEMENT IN CONNECTION WITH RECENT REGISTERED DIRECT OFFERING

Athersys, Inc. | September 26, 2022

news image

Athersys, Inc. a regenerative medicine company developing MultiStem® for critical care indications, announced that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor. The Purchase Agreement contains certain restrictions that, s...

Read More

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

news image

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More

SESTINA BIO LAUNCHES ENGINEERING BIOLOGY TO CREATE REVOLUTIONARY PRODUCTS

Sestina Bio | October 17, 2020

news image

Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usuall...

Read More
news image

Industrial Impact

ATHERSYS AMENDS SECURITIES PURCHASE AGREEMENT IN CONNECTION WITH RECENT REGISTERED DIRECT OFFERING

Athersys, Inc. | September 26, 2022

Athersys, Inc. a regenerative medicine company developing MultiStem® for critical care indications, announced that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor. The Purchase Agreement contains certain restrictions that, s...

Read More
news image

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More
news image

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More
news image

SESTINA BIO LAUNCHES ENGINEERING BIOLOGY TO CREATE REVOLUTIONARY PRODUCTS

Sestina Bio | October 17, 2020

Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usuall...

Read More